Medically reviewed by Richard N. Fogoros, MD Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease that develops when ...

Medically reviewed by Laura Campedelli, DPT Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, potentially life-threatening disorder. It causes the red blood cells to break apart, a process ...

Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the ...

The mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion's infusion therapy Soliris, but Novartis' iptacopan could provide an oral option after ...

vying to become an oral alternative to injectable therapies for ultra-rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH). The Swiss pharma group said this morning that the top-line ...

(RTTNews) - Omeros Corp. (OMER), Friday announced that it has initiated clinical trial site activation for its Phase 3 program evaluating zaltenibart or OMS906 in paroxysmal nocturnal ...